Acute Myeloid Leukemia Registry

Recruiting

• Conditions: Acute Myeloid Leukemia

• Registration Number: NCT05979675
• Lead Sponsor: Turkish Hematology Association

Brief Summary

All acute myeloid leukemia (AML) patients diagnosed after 1 Jan 2020 will be included to this study.

Detailed Description

This is a non interventional prospective disease registry, 250 prospective patients diagnosed with AML across 20 centers in Turkey.

Participating sites will consist of hematology clinics and routine follow-up procedures will be followed-up.

All patients diagnosed after 1 Jan 2020 as AML will be included and patients will be enrolled during 24 months of period and will be followed-up 36 months. Study will be completed in 60 months.

Study Timeline

• Study Start: 2021-12-21
• Status Verified: 2023-07
• Study First Submitted: 2023-07-29
• Study First Submitted QC: 2023-07-29
• Last Update Submitted: 2023-07-29
• Study First Posted: 2023-08-07
• Last Update Posted: 2023-08-07
• Primary Completion: 2026-12-21
• Study Completion: 2026-12-21

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 250

Inclusion Criteria

• Diagnosed as AML after 1 Jan 2020
• Patients signed informed consent form

Exclusion Criteria

• Patients under 18 years old

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Overall Survival	60 months	From diagnosis to exits by any cause

Trial Locations

Locations (1)

Antalya Training and Research Hospital; 🇹🇷 Antalya, Turkey